Gaucher disease (MIM #230800), the inherited deficiency of the lysosomal enzyme glucocerebrosidase (EC 3.2.1.45), manifests with diverse clinical symptoms, including progressive neurologic deterioration. Gaucher disease was first described in 1882 by Gaucher (1) . It has long been accepted that the accumulation of glucocerebroside in reticuloendothelial cells underlies the pathogenesis of Gaucher disease, transforming macrophages throughout the reticuloendothelial system into characteristic Gaucher cells, the hallmark pathologic finding of the disease (2, 3) . However, the pathophysiologic mechanism leading to the neurologic symptoms seen in this disorder remains unknown (4 -6) . Glucocerebroside, which is widely distributed in cellular membranes, is released during the turnover of senescent white and red blood cell membranes, and is a metabolic intermediate in both the synthesis and degradation of complex glycosphingolipids, including gangliosides and globoside. Glucocerebroside is predominantly degraded within lysosomes by glucocerebrosidase to glucose and ceramide, the latter being further degraded by ceramidase to sphingosine and fatty acids (7, 8) . The accumulation of glucocerebroside in the liver, spleen, and bone marrow contributes to the massive organ enlargement and decreased red blood cells and platelets, as well as the skeletal deterioration, seen in patients with Gaucher disease.
Type 2, or acute neuronopathic Gaucher disease (MIM #230900), is the most rare and severe form of Gaucher disease, usually resulting in death in infancy (9, 10) . The devastating neurologic deterioration seen in patients with type 2 Gaucher disease has been attributed to the accumulation of glucocerebroside in the brain. However, many aspects of the pathology encountered in Gaucher disease are not well explained solely by the storage of glucocerebroside. For example, the amount of glucocerebroside in liver samples from patients with Gaucher disease is not sufficient to account for the degree of hepatomegaly on the basis of mass effect. Likewise, the relatively limited CNS pathology and storage found in patients and mice with type 2 Gaucher disease as compared to the rapidly progressive neurologic deterioration observed (11) . Neither the amount of stored lipid nor the level of the residual glucocerebrosidase activity correlate well with patient phenotypes (12) . Even the relationship between genotype and phenotype in patients with Gaucher disease is complex, and it is often difficult to correlate specific symptoms with a unique genotype (13, 14) .
The enzyme glucocerebrosidase also degrades another substrate, Glc-sph, to glucose and sphingosine. Patients with both type 2 and 3 Gaucher disease accumulate Glc-sph in tissues, including the cerebral and cerebellar cortex (15) . Nilsson and Svennerholm (15) suggested that this toxic substance, also known as glucosylpsychosine, could be responsible for the neuropathology seen in Gaucher disease. Moreover, it has been suggested that Glc-sph can disrupt normal cell activity by interfering with signal transduction and cellular differentiation (16) , and may be involved in programmed cell death (17) .
A murine model of type 2 Gaucher disease with a null allele was created by targeted homologous recombination to enable a better understanding of the pathophysiology of this disorder (18) . For this model, portions of exons 9 and 10 of the murine glucocerebrosidase gene were removed and replaced with a selectable neomycin marker. Homozygous mice with type 2 Gaucher disease accumulate glucocerebroside in tissues, particularly within lysosomes of macrophages, as demonstrated by both thin layer chromatography and electron microscopy (19, 20) . A pathologic examination of the nervous system, performed in an attempt to explain the rapid postnatal death of the mice and patients severely affected with type 2 Gaucher disease, demonstrated remarkably mild cellular and tissue pathology, even in the brain, despite the elevated glucocerebroside levels (19) . No definite pathologic changes were observed at the light microscopic level, and typical Gaucher cells were not seen. However, electron microscopic studies revealed an accumulation of glucocerebroside within lysosomes. In the brain, the stored glucocerebroside was found predominantly in microglial cells and only to a very limited extent in certain sensory and motor neurons. Purkinje cells and neurons of the cerebellar and cerebral cortex were free of glucocerebroside (19) . These findings make it difficult to attribute the early demise of the type 2 mice and human neonates solely to glucocerebroside storage.
As an alternative explanation for the rapid clinical deterioration seen in type 2 Gaucher disease, we studied the accumulation of Glc-sph in brain, liver, and spleen from mice with type 2 Gaucher disease. We also measured the level of this glycosphingolipid at different stages of gestation in affected humans and mice. On the basis of our findings, we suggest that Glc-sph rather than glucocerebroside may be responsible for the neuropathology observed in type 2 Gaucher disease.
METHODS

Chemicals.
Glc-sph, Gal-sph, and NBD-F were obtained from Sigma Chemical Company (St. Louis, MO, U.S.A.).
Animals and tissue preparation. All animal studies were approved by the Animal Care and Use Committee of the National Institute of Mental Health. A colony of heterozygous type 2 Gaucher mice (18) has been maintained in our laboratory, as well as the Jackson Laboratory mutant mouse collection. Mating between heterozygote mice produced homozygous offspring as well as heterozygous and wild-type littermates. Although homozygous mice with type 2 Gaucher disease were easily identified clinically, PCR-based genotyping was performed on DNA obtained from mouse tails. Homozygous and heterozygous mice were identified by the presence of the NeoR, which replaced portions of exons 9 and 10 of the murine glucocerebrosidase. Long PCR was performed with a forward primer from exon 9 (GAACCTCCTTTAC-CACGTAACTGG) and reverse primer from intron 10 (CGT-GTGAGGTGGCTGGCATC) of the murine glucocerebrosidase gene using the enzyme Elongase (Life Technology, Gaithersburg, MD, U.S.A.), an annealing temperature of 57°C, and 35 amplification cycles. Using these conditions, a 668-bp product was amplified from the wild-type allele, whereas the null glucocerebrosidase allele with NeoR resulted in a 2.1-kb amplification product. The preparation of animal tissues was performed as described previously (19) .
Human fetal tissues. Frozen autopsy tissues were received from two human fetuses affected with type 2 Gaucher disease. The diagnosis was established by both enzymatic and molecular analyses. The two fetuses were conceived by the same nonconsanguineous parents, and the pregnancies ended at 11 and 22 wk of gestation. Both fetuses were found to have severe hydrops fetalis (21) . Molecular analyses were performed on fetal and parental DNA, collected with informed consent under a protocol approved by the National Institute of Mental Health Institute Review Board. These studies revealed that the father carried a novel recombinant allele resulting from a fusion between the glucocerebrosidase gene and its pseudogene, beginning in intron 3. The maternal mutation was a rare T to G splice junction mutation in intron 10 (21). Frozen autopsy and pathologic samples from controls were purchased from the Cooperative Human Tissue Network (Philadelphia, PA, U.S.A.) and the Central Laboratory for Human Embryology (Seattle, WA, U.S.A.).
Fetal mouse tissues. Murine embryos from timed heterozygote-heterozygote matings were obtained at specific days of gestation (E10, E13, E15, E18, and E21). All littermates were genotyped, and the tissues were analyzed for Glc-sph content. Matings continued until the number of homozygous embryos at each day studied was adequate for statistical analysis. Because of the limited size of the organs in these early embryos, especially the spleen, lipid levels were measured from the head (including the brain) and were compared with levels in the rest of the body.
Glc-sph extraction and isolation. Fresh tissue was placed in a 15-mL polypropylene tube, and approximately 100 mg of wet weight tissue was homogenized with 5 mL of chloroformmethanol (2:1, vol/vol). A 0.5-mL aliquot was withdrawn for protein determination. For lipid analysis, the homogenate was kept at room temperature for 1 h and then filtered through a 0.22-m membrane (Millipore, Bedford, MA, U.S.A.). One microgram of Gal-sph was added to the filtrate as an internal standard. The lipid extract was evaporated under nitrogen to a 234 volume of approximately 2 mL and applied to a cationic AG 50W-X8 column (1 ϫ 15 cm, 1.5 mL bed volume, sodium form; BioRad, Richmond, CA, U.S.A.). The column was washed successively with 4 mL of methanol, 8 mL of chloroform/methanol (2:1, vol/vol), and 4 mL of methanol, and then eluted with 4 mL of methanol-aqueous 0.4 M CaCl 2 (3:1, vol/vol). An equal volume of water (4 mL) was added to the eluate, and the mixture was applied to a C18 Sep-Pak cartridge (Waters Associates, Milford, MA, U.S.A.), which was activated with methanol and washed with water before use. The cartridge was washed with 20 mL of water, and sphingosines were eluted with 3 mL of methanol, and 3 mL of chloroformmethanol (2:1, vol/vol). The eluate was evaporated to dryness under nitrogen.
Sphingosine derivatization with NBD-F. Aliquots containing 10 g of both Glc-sph and Gal-sph or the nitrogen-dried sample eluate (see above) were dissolved in 100 L of methanol/0.1 M phosphate buffer (pH 8.0, 50% vol/vol). Five microliters of NBD-F (80 mM, 14.6 mg/mL of methanol) was added, and the mixture was heated at 70°C for 1 min.
HPLC analyses of derivatized Glc-sph and Gal-sph. Aliquots of the samples were diluted 1:100 in a mobile phase (2% water in acetonitrile) and analyzed for Glc-sph and Gal-sph by HPLC, using two 114 Solvent Delivery Modules controlled with a 421 Controller (Beckman, Fullerton, CA, U.S.A.). A Shodex Sugar column SZ 5532 (5 mm ϫ 16 cm, internal diameter) with a Shodex Sugar SZ precolumn (Showa Denko, Tokyo, Japan) was used for the separation of Glc-sph and Gal-sph, which was performed in acetonitrile-water (98:2, vol/vol) with a flow rate of 1 mL/min. The column was heated at 55°C. A Waters 474 scanning fluorescence detector, with excitation and emission wavelengths of 470 nm and 530 nm, respectively, was used to detect peaks. Data were collected for analysis, and peak areas were calculated on a Dionex chromatography data station using the Advanced Computer Interface (Dionex, Sunnyvale, CA, U.S.A.).
Statistical analyses
The significance of differences between the homozygous null, heterozygous null, and wild-type mice was analyzed using a paired t test. Experimental results are expressed in the form of mean Ϯ SD, and n indicates the number of different mice studied.
RESULTS
Quantitation of Glc-sph.
The quantitation of Glc-sph was achieved by HPLC separation of NBD-F-generated autofluorescent derivatives (22) that were detectable in the picomole range. Linearity was demonstrated over concentrations ranging 100-fold. The efficiency of the extraction of Glc-sph from tissues was quantitated by the addition of a standard amount of Gal-sph to the samples.
Analysis of Glc-sph in tissues from mice with type 2 Gaucher disease. The separation of Glc-sph and Gal-sph (used as an internal standard) isolated from brain tissue from heterozygous and homozygous mice with type 2 Gaucher disease at birth is shown in Figure 1 . Mice with type 2 Gaucher disease accumulated 50 -100 times more Glc-sph in brain (633.0 Ϯ 92 ng/mg protein; n ϭ 7) compared with heterozygous (13.6 Ϯ 7 ng/mg protein; n ϭ 7) and wild-type (6.4 Ϯ 3 ng/mg protein; n ϭ 8) littermates (p Յ 0.0001; Table 1 ). No statistical significance was found between the Glc-sph levels in heterozygous and wild-type littermates. Glc-sph levels were also markedly elevated in both liver (555.7 Ϯ 59 ng/mg protein; p ϭ 0.0007) and spleen (732.1 Ϯ 87 ng/mg protein; p ϭ 0.0009) from homozygous mice with type 2 Gaucher disease (Table 1) compared with nonaffected littermates.
Glc-sph accumulation in embryonic mice with type 2 Gaucher disease. Early mouse embryos were studied by measuring Glc-sph in both the head portion and the remainder of the body. Glc-sph was measured at E 10, E 13, E 15, E 18, and E 21 d of gestation, and the numbers of homozygous null mice studied at each time point were 3, 4, 3, 3, and 7, respectively. Elevations of Glc-sph were detected in utero in mice with type 2 Gaucher disease by E13 and progressively increased throughout gestation both in the head and the body (Fig. 2) . The amount of Glc-sph in control littermates was 7 Ϯ 4 ng/mg protein, and at least two control embryos were assayed at each gestational date.
Analysis of Glc-sph in tissues from human fetuses with type 2 Gaucher disease. Glc-sph levels were measured in different tissues from two human fetuses with type 2 Gaucher disease, received as pathology specimens at 11 and 22 wk of gestation. The Glc-sph levels for each tissue are shown in Table 2 . Significant elevations of Glc-sph were observed in both fetuses compared with tissues levels in three control fetuses (gestational ages 13 to 15 wk), in which Glc-sph levels were negligible (Table 2 ). 
GLUCOSYLSPHINGOSINE IN GAUCHER DISEASE
DISCUSSION
Many unresolved questions remain regarding both the pathophysiology of type 2 Gaucher disease and the mechanisms resulting in the wide range of phenotypic differences encountered in patients with glucocerebrosidase deficiency. Neither the levels of residual glucocerebrosidase activity, the amount of accumulated glucocerebroside, nor the PCR-defined genotype can be used to reliably predict the clinical course. The availability of a mouse model of type 2 Gaucher disease has permitted a more detailed evaluation of the biochemical and ultrastructural changes occurring in neuronopathic Gaucher disease. Like human infants with type 2 Gaucher disease, the null allele mice die in early infancy and have elevated levels of glucocerebroside in brain and other tissues. However, the limited amount of cellular pathology observed throughout the CNS suggests that the rapid demise and neurologic deterioration encountered is not solely related to glucocerebroside storage. The average Glc-sph level in brains of newborn homozygous mice with type 2 Gaucher disease is shown to be 633.0 Ϯ 92 ng/mg protein, which is approximately 100-fold greater than that of wild-type littermates. Similar increases in Glc-sph levels were observed in the liver and the spleen of the mice with type 2 Gaucher disease, but not in controls or heterozygotes. Although it has been suggested that chemical degradation of sphingolipids to the corresponding lyso-compound may occur under postmortem conditions (23) we were able to address this concern by simultaneously studying littermates.
The animal model also enabled us to study the accumulation of Glc-sph during development. In the mice with type 2 Gaucher disease Glc-sph was detectable in utero by E13, and Glc-sph levels progressively increased throughout gestation both in the brain and in the visceral organs.
These findings in the mice with type 2 Gaucher disease confirm and extend earlier studies performed by Nilssen and Svennerholm (15) , which demonstrated that Glc-sph, which is ordinarily not detected in normal human brain, is markedly elevated in brains from patients with type 2 and 3 Gaucher disease. In fact, the highest values were reported from patient samples from the most fulminant cases. These observations suggested that the cytotoxic substance, Glc-sph, could be involved in the neuronal loss in Gaucher disease. Moreover, in another lysosomal storage disorder, Krabbe disease, the inherited deficiency of galactosylceramidase (EC 3.2.1.46), a sphingosine derivative, is directly implicated in the CNS damage observed (24) . In both a naturally occurring murine model of this disorder, the Twitcher mouse, and patients with Krabbe disease, there is an accumulation of Gal-sph (galactosylpsychosine), which leads to the loss of oligodendroglia (23) (24) (25) .
The in utero accumulation of Glc-sph observed in the mice with type 2 Gaucher disease was also seen in tissues from humans affected with type 2 Gaucher disease. The lipid determinations performed on tissues obtained from two fetuses, both diagnosed prenatally with type 2 Gaucher disease, reveal Glc-sph storage occurring as early as 11 wk of gestation. The levels of Glc-sph in the human fetuses were quite close to those of mice at comparable stages of gestation. Compared with Glc-sph levels in tissue from control human fetuses, the Glcsph levels in the fetuses with type 2 Gaucher disease suggest advanced and progressive accumulation analogous to the storage observed in mice with type 2 Gaucher disease. Clinically, these findings have important implications. They suggest that a toxic stimulus is present long before birth, and that therapy begun during infancy may do little to prevent the progressive neurologic damage that began early in gestation.
We have measured brain Glc-sph levels in seven patients with Gaucher disease (26) . Five of the patients studied had type 2 Gaucher disease, and the levels of Glc-sph ranged from 9.8 to 935 ng/mg protein. A patient with type 3 Gaucher disease had a Glc-sph level of 8.9 ng/mg protein. The brain Glc-sph level, measured in one adult patient with type 1 Gaucher disease who died at age 69 years, was 0.34 ng/mg protein, which was in the range detected in six control adult brain samples (0.1-1.4 ng/mg protein, mean 0.6 ng/mg protein). In the literature, the brain Glc-sph level was quantified in a single patient who died at age 13 years and was believed to have type 1 Gaucher disease (27) . Here the concentration of Glc-sph in the cerebral cortex was reported to be 0.7 nmole/g, which was higher than the controls (Ͻ0.01 nmole/g) but well below values that they reported for their patients with type 2 Gaucher disease (3.9 -14.8 nmole/g) (27) .
It is now appreciated that glycolipids, once thought to serve only as structural components of cells, are important in signal pathways, cellular senescence, and programmed cell death (16, 28) . Studies have shown that Glc-sph can inhibit the growth of certain cells in culture (29) . Glc-sph, as well as Gal-sph and sphingosine, is a potent inhibitor of mitochondrial cytochrome c oxidase (30) and protein kinase C activity (16, 28) , and could disrupt cell activity by interfering with signal transduction and cellular differentiation. Furthermore, both sphingosine and ceramides have been implicated as mediators of apoptosis (17) . Thus, the Glc-sph accumulation noted in patients and mice with type 2 Gaucher disease may have far-reaching effects. Studies are currently under way to better establish a mechanistic basis for the cellular toxicity of Glc-sph. Our current results provide further evidence that Glc-sph may be involved in the cause of the neuronopathic forms of Gaucher disease because 1) brain Glc-sph is markedly elevated in mice with type 2 Gaucher disease, 2) Glc-sph is also elevated in tissues including brain from human fetuses with type 2 Gaucher disease, and 3) mice with type 2 Gaucher disease progressively accumulate Glc-sph throughout gestation. Although the accumulation of both glucocerebroside and Glc-sph in patients with Gaucher disease is a direct consequence of glucocerebrosidase deficiency, the origin of the stored Glc-sph and its metabolism still require better characterization. The accumulation of Glc-sph during embryonic development could result in irreversible damage to the developing nervous system and lead to the devastating clinical course seen in mice and patients with type 2 Gaucher disease. 
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